241 related articles for article (PubMed ID: 35501851)
1. DNA repair and damage pathways in mesothelioma development and therapy.
Malakoti F; Targhazeh N; Abadifard E; Zarezadeh R; Samemaleki S; Asemi Z; Younesi S; Mohammadnejad R; Hadi Hossini S; Karimian A; Alemi F; Yousefi B
Cancer Cell Int; 2022 May; 22(1):176. PubMed ID: 35501851
[TBL] [Abstract][Full Text] [Related]
2. CAMK2D: a novel molecular target for BAP1-deficient malignant mesothelioma.
Karnan S; Ota A; Murakami H; Rahman ML; Wahiduzzaman M; Hasan MN; Vu LQ; Hanamura I; Inoko A; Riku M; Ito H; Kaneko Y; Hyodo T; Konishi H; Tsuzuki S; Hosokawa Y
Cell Death Discov; 2023 Jul; 9(1):257. PubMed ID: 37479714
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma.
Sartore-Bianchi A; Gasparri F; Galvani A; Nici L; Darnowski JW; Barbone D; Fennell DA; Gaudino G; Porta C; Mutti L
Clin Cancer Res; 2007 Oct; 13(19):5942-51. PubMed ID: 17908991
[TBL] [Abstract][Full Text] [Related]
4. Asbestos-induced chronic inflammation in malignant pleural mesothelioma and related therapeutic approaches-a narrative review.
Zolondick AA; Gaudino G; Xue J; Pass HI; Carbone M; Yang H
Precis Cancer Med; 2021 Sep; 4():. PubMed ID: 35098108
[TBL] [Abstract][Full Text] [Related]
5. Germline mutations in DNA repair genes predispose asbestos-exposed patients to malignant pleural mesothelioma.
Betti M; Casalone E; Ferrante D; Aspesi A; Morleo G; Biasi A; Sculco M; Mancuso G; Guarrera S; Righi L; Grosso F; Libener R; Pavesi M; Mariani N; Casadio C; Boldorini R; Mirabelli D; Pasini B; Magnani C; Matullo G; Dianzani I
Cancer Lett; 2017 Oct; 405():38-45. PubMed ID: 28687356
[TBL] [Abstract][Full Text] [Related]
6. Genetic predisposition for malignant mesothelioma: A concise review.
Betti M; Aspesi A; Sculco M; Matullo G; Magnani C; Dianzani I
Mutat Res Rev Mutat Res; 2019; 781():1-10. PubMed ID: 31416570
[TBL] [Abstract][Full Text] [Related]
7. Malignant mesothelioma as an oxidative stress-induced cancer: An update.
Chew SH; Toyokuni S
Free Radic Biol Med; 2015 Sep; 86():166-78. PubMed ID: 25975982
[TBL] [Abstract][Full Text] [Related]
8. The secretome signature of malignant mesothelioma cell lines.
Manfredi M; Martinotti S; Gosetti F; Ranzato E; Marengo E
J Proteomics; 2016 Aug; 145():3-10. PubMed ID: 26921831
[TBL] [Abstract][Full Text] [Related]
9. Sensitivity to asbestos is increased in patients with mesothelioma and pathogenic germline variants in BAP1 or other DNA repair genes.
Betti M; Aspesi A; Ferrante D; Sculco M; Righi L; Mirabelli D; Napoli F; Rondón-Lagos M; Casalone E; Vignolo Lutati F; Ogliara P; Bironzo P; Gironi CL; Savoia P; Maffè A; Ungari S; Grosso F; Libener R; Boldorini R; Valiante M; Pasini B; Matullo G; Scagliotti G; Magnani C; Dianzani I
Genes Chromosomes Cancer; 2018 Nov; 57(11):573-583. PubMed ID: 30338612
[TBL] [Abstract][Full Text] [Related]
10. Inactivation of Tp53 and Pten drives rapid development of pleural and peritoneal malignant mesotheliomas.
Sementino E; Menges CW; Kadariya Y; Peri S; Xu J; Liu Z; Wilkes RG; Cai KQ; Rauscher FJ; Klein-Szanto AJ; Testa JR
J Cell Physiol; 2018 Nov; 233(11):8952-8961. PubMed ID: 29904909
[TBL] [Abstract][Full Text] [Related]
11. PARP1 inhibition affects pleural mesothelioma cell viability and uncouples AKT/mTOR axis via SIRT1.
Pinton G; Manente AG; Murer B; De Marino E; Mutti L; Moro L
J Cell Mol Med; 2013 Feb; 17(2):233-41. PubMed ID: 23301673
[TBL] [Abstract][Full Text] [Related]
12. Analysis of CCDC6 as a novel biomarker for the clinical use of PARP1 inhibitors in malignant pleural mesothelioma.
Morra F; Merolla F; D'Abbiero D; Ilardi G; Campione S; Monaco R; Guggino G; Ambrosio F; Staibano S; Cerrato A; Visconti R; Celetti A
Lung Cancer; 2019 Sep; 135():56-65. PubMed ID: 31447003
[TBL] [Abstract][Full Text] [Related]
13. BAP1 protein is a progression factor in malignant pleural mesothelioma.
Arzt L; Quehenberger F; Halbwedl I; Mairinger T; Popper HH
Pathol Oncol Res; 2014 Jan; 20(1):145-51. PubMed ID: 23963927
[TBL] [Abstract][Full Text] [Related]
14. The role of apoptosis defects in malignant mesothelioma pathogenesis with an impact on prognosis and treatment.
Galani V; Varouktsi A; Papadatos SS; Mitselou A; Sainis I; Constantopoulos S; Dalavanga Y
Cancer Chemother Pharmacol; 2019 Aug; 84(2):241-253. PubMed ID: 31119375
[TBL] [Abstract][Full Text] [Related]
15. Molecular pathways: targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma.
Carbone M; Yang H
Clin Cancer Res; 2012 Feb; 18(3):598-604. PubMed ID: 22065079
[TBL] [Abstract][Full Text] [Related]
16. Minimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma.
Napolitano A; Pellegrini L; Dey A; Larson D; Tanji M; Flores EG; Kendrick B; Lapid D; Powers A; Kanodia S; Pastorino S; Pass HI; Dixit V; Yang H; Carbone M
Oncogene; 2016 Apr; 35(15):1996-2002. PubMed ID: 26119930
[TBL] [Abstract][Full Text] [Related]
17. Mesothelioma Mouse Models with Mixed Genomic States of Chromosome and Microsatellite Instability.
Song Y; Baxter SS; Dai L; Sanders C; Burkett S; Baugher RN; Mellott SD; Young TB; Lawhorn HE; Difilippantonio S; Karim B; Kadariya Y; Pinto LA; Testa JR; Shoemaker RH
Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804881
[TBL] [Abstract][Full Text] [Related]
18. Germline mutation of Bap1 accelerates development of asbestos-induced malignant mesothelioma.
Xu J; Kadariya Y; Cheung M; Pei J; Talarchek J; Sementino E; Tan Y; Menges CW; Cai KQ; Litwin S; Peng H; Karar J; Rauscher FJ; Testa JR
Cancer Res; 2014 Aug; 74(16):4388-97. PubMed ID: 24928783
[TBL] [Abstract][Full Text] [Related]
19. Mesothelioma review.
Montjoy C; Parker J; Petsonk L; Luis T; Fallon K
W V Med J; 2009; 105(3):13-6. PubMed ID: 19456032
[TBL] [Abstract][Full Text] [Related]
20. BAP1 mutation is a frequent somatic event in peritoneal malignant mesothelioma.
Alakus H; Yost SE; Woo B; French R; Lin GY; Jepsen K; Frazer KA; Lowy AM; Harismendy O
J Transl Med; 2015 Apr; 13():122. PubMed ID: 25889843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
